R Dummer|S Rozati|N Eggmann|J Rinderknecht|S M Goldinger

Showing results (1-10 of 265) with videos related to

Pageof 27

Sort By:

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012

From chemotherapy to targeted treatmentR Dummer, S Rozati, N Eggmann, et al.

Praxis|July 20, 2012

[Therapeutic approaches in Melanoma - a paradigm for personalized medicine]R Dummer, S Goldinger, J Rinderknecht, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2014

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)R Dummer, M Duvic, J Scarisbrick, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2017

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanomaV C Amann, D Hoffmann, J Mangana, et al.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|November 15, 2012

Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomasW Kempf, S Rozati, K Kerl, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2007

Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligoS M Goldinger, R Dummer, P Schmid, et al.

European Journal of Cancer (Oxford, England : 1990)|August 7, 2016

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effectsU Urner-Bloch, M Urner, N Jaberg-Bentele, et al.

The British Journal of Dermatology|December 15, 2015

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation statusA L Frauchiger, J Mangana, M Rechsteiner, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 8, 2016

Developments in targeted therapy in melanomaV C Amann, E Ramelyte, S Thurneysen, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|November 24, 2018

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanomaN P Graf, P Koelblinger, N Galliker, et al.

Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:

Pageof 27

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012

From chemotherapy to targeted treatmentR Dummer, S Rozati, N Eggmann, et al.

Praxis|July 20, 2012

[Therapeutic approaches in Melanoma - a paradigm for personalized medicine]R Dummer, S Goldinger, J Rinderknecht, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2014

Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2017

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanomaV C Amann, D Hoffmann, J Mangana, et al.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|November 15, 2012

Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomasW Kempf, S Rozati, K Kerl, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2007

Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligoS M Goldinger, R Dummer, P Schmid, et al.

European Journal of Cancer (Oxford, England : 1990)|August 7, 2016

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effectsU Urner-Bloch, M Urner, N Jaberg-Bentele, et al.

The British Journal of Dermatology|December 15, 2015

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation statusA L Frauchiger, J Mangana, M Rechsteiner, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 8, 2016

Developments in targeted therapy in melanomaV C Amann, E Ramelyte, S Thurneysen, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|November 24, 2018

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanomaN P Graf, P Koelblinger, N Galliker, et al.

Pageof 27